Phase I clinical trial of a human idiotypic p53 vaccine in patients with advanced malignancy.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Annals of Oncology

• Publication date

  2004-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/ANNONC/MDH053PMID 14760129
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Issues on clinical applications of cancer vaccines.

  2001cited by this paper
• Isolation of human antibodies against the central DNA binding domain of p53 from an individual with colorectal cancer using antibody phage display.

  2001cited by this paper
• Intradermal ras peptide vaccination with granulocyte‐macrophage colony‐stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma

  2001cited by this paper
• Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution.

  2000cited by this paper
• High steady-state levels of p53 are not a prerequisite for tumor eradication by wild-type p53-specific cytotoxic T lymphocytes.

  2000cited by this paper
• Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2.

  2000cited by this paper
• Systemic lupus erythematosus in mice, spontaneous and induced, is associated with autoimmunity to the C‐terminal domain of p53 that recognizes damaged DNA

  2000cited by this paper
• Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen.

  1999cited by this paper
• Generation of anti-p53 Fab fragments from individuals with colorectal cancer using phage display.

  1999cited by this paper
• Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.

  1999cited by this paper
• Immunization with recombinant human granulocyte-macrophage colony-stimulating factor as a vaccine adjuvant elicits both a cellular and humoral response to recombinant human granulocyte-macrophage colony-stimulating factor.

  1999cited by this paper
• Idiotypic immunization induces immunity to mutated p53 and tumor rejection

  1998cited by this paper
• Immunity to p53 induced by an idiotypic network of anti-p53 antibodies: generation of sequence-specific anti-DNA antibodies and protection from tumor metastasis.

  1998cited by this paper
• In‐vivo immune responses to idiotypic VH complementarity‐determining region 3 peptide vaccination in B‐cell non‐Hodgkin's lymphoma

  1998cited by this paper
• Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas.

  1998cited by this paper
• Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen.

  1997cited by this paper
• Tumor Eradication by Wild-type p53-specific Cytotoxic T Lymphocytes

  1997cited by this paper
• Tumor-suppressor effects of anti-p53 IgG on chemically induced colon cancer in rats

  1997cited by this paper
• Therapy of murine tumors with p53 wild-type and mutant sequence peptide- based vaccines

  1996cited by this paper
• Granulocyte‐macrophage‐colony‐stimulating factor enhances immune responses to melanoma‐associated peptides in vivo

  1996cited by this paper
• Induction of antigen-specific T and B cell immunity in colon carcinoma patients by anti-idiotypic antibody.

  1995cited by this paper
• Targeting p53 as a general tumor antigen.

  1995cited by this paper
• Immune responses in patients with T-cell lymphoma treated with an anti-idiotype antibody mimicking a highly restricted T-cell antigen.

  1995cited by this paper
• Primary proliferative T cell response to wild‐type p53 protein in patients with breast cancer

  1995cited by this paper
• Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers

  1994cited by this paper
• A mouse mutant p53 product recognized by CD4+ and CD8+ T cells.

  1994cited by this paper
• Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen.

  1994cited by this paper
• Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies.

  1991cited by this paper
• Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form.

  1990cited by this paper
• Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer

  1982cited by this paper
• Towards a network theory of the immune system.

  1974cited by this paper
• Speculations on idiotypes and homobodies.

  1973cited by this paper
• Towards a network theory of the immune system.

  1973cited by this paper

• The search for a TNBC vaccine: the guardian vaccine

  2025cites this paper
• Fueling Cancer Vaccines to Improve T Cell-Mediated Antitumor Immunity

  2022cites this paper
• Clinical and Immunological Effects of p53-Targeting Vaccines

  2021cites this paper
• NAPPA-Based Vaccines for a New Proteogenomics Approach for Public Health

  2015cites this paper
• Immunological and Clinical Effects of Vaccines Targeting p53-Overexpressing Malignancies

  2011cites this paper
• Construction of a triple modified p53 containing DNA vaccine to enhance processing and presentation of the p53 antigen.

  2009cites this paper
• Recent advances in validating MDM2 as a cancer target.

  2009cites this paper
• Cutaneous delivery of prophylactic and therapeutic vaccines: historical perspective and future outlook

  2008cites this paper
• Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation.

  2008cites this paper
• Recombinant, refolded tetrameric p53 and gonadotropin-releasing hormone-p53 slow proliferation and induce apoptosis in p53-deficient cancer cells

  2008cites this paper
• Novel immunotherapeutic strategies for gynaecologic malignancies

  2008cites this paper
• Phase II trial of anti‐idiotypic p53 peptides (Pentrys) plus granulocyte‐macrophage colony‐stimulating factor in patients with hormone‐refractory prostate cancer

  2007cites this paper
• Increased frequencies of CD8+ T lymphocytes recognizing wild‐type p53‐derived epitopes in peripheral blood correlate with presence of epitope loss tumor variants in patients with hepatocellular carcinoma

  2006cites this paper
• Design of peptide-based vaccines for cancer.

  2006cites this paper
• Peptidinhibitoren zur Vermittlung von Stressreaktionen

  2005cites this paper
• Immunologic therapies for gastrointestinal cancers.

  2005cites this paper
• Murine mammary adenocarcinoma cells transfected with p53 and/or Flt3L induce antitumor immune responses

  2005cites this paper